Clinical Trials

Cambridge Antibody Tech Group PLC
25 September 2001

FOR IMMEDIATE RELEASE
07.00 BST, 02.00 EST Tuesday 25 September 2001

For Further Information Contact:

Cambridge Antibody Technology               Square Mile BSMG Worldwide (Europe)

Tel: [phone]                   Tel: [phone]

David Glover, Medical Director              Kevin Smith

John Aston, Finance Director                Graham Herring

Rowena Gardner, Head of Corporate
Communications
                                            BMC Communications/The Trout Group
                                            (USA)

                                            Tel: [phone]

                                            Brad Miles, ext 17 (media)

                                            Brandon Lewis, ext.15 (investors)

 CAT ANNOUNCES GRANTING OF REGULATORY APPROVAL TO START UK PATIENT TRIALS OF
                                  CAT - 213

Melbourn, UK ...Cambridge Antibody Technology (LSE:CAT; NASDAQ: CATG) today
announced that it has received a CTX (Clinical Trial Exemption) from the UK
Medicines Control Agency allowing it to commence phase I/IIa clinical trials
in patients with CAT-213, a human anti-eotaxin1 monoclonal antibody.

CAT-213 is in development for the treatment of severe allergic disorders and
may also be useful in the management of patients with hypereosinophilia. A
phase I study in 25 healthy volunteers was recently completed with no safety
concerns after single intravenous doses of up to 10mg/kg.

The new phase I/IIa double-blind clinical trial will take place in two UK
investigational sites and will study the effects of CAT-213 or placebo upon
patients with allergic rhinitis who are challenged with nasal allergen. It is
expected that patient enrollment will commence in October 2001 and be
completed before the 2002 UK hay fever season.

 Commenting on the news, Dr David Glover, CAT's Medical Director, said, 'We
are very pleased to have received approval to start patient trials with
CAT-213. The new clinical trial will represent the first human proof of
principle study that CAT-213 can modulate the effects of eosinophils in an
allergic setting'.

CAT-213 is the fifth human monoclonal antibody from CAT to enter clinical
trials and is the third human monoclonal antibody that CAT itself has taken to
this stage.

-ENDS-

Notes to Editors:

Cambridge Antibody Technology (CAT)

CAT is a UK biotechnology company using its proprietary technologies in human
monoclonal antibodies for drug discovery and drug development. Based in
Melbourn, 10 miles south of Cambridge, England, CAT currently employs around
250 people.

CAT is listed on the London Stock Exchange, having raised £41m in its IPO in
March 1997. A further offering in March 2000 raised £93m. Also, CAT's ADRs are
listed on the US NASDAQ National Market.

CAT has an advanced platform technology for rapidly isolating human monoclonal
antibodies using phage display systems. CAT has extensive phage antibody
libraries, currently incorporating around 100 billion distinct antibodies.
These libraries form the basis for the company's strategy to develop a
portfolio of clinical development programmes. Five human therapeutic
antibodies developed by CAT are at various stages of clinical trials.

CAT has a number of licence and collaborative agreements in place with
pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer,
Genentech, ICOS, Genetics Institute, Wyeth-Ayerst, Human Genome Sciences,
Knoll Pharmaceuticals (a subsidiary of Abbott Pharmaceuticals), Pharmacia,
Oxford GlycoSciences, Genzyme, Immunex, Zyomyx and Elan.

CAT-213

CAT-213 is a human IgG4 monoclonal antibody that neutralises eotaxin1 - a
chemokine protein that acts to attract eosinophils (a type of white blood
cell) into tissues, where they can degranulate causing tissue damage.
Eosinophils are thus believed to play a key role in causing the inflammation
and tissue damage that occurs in a variety of allergic disorders, including
asthma.

Allergies in some form affect over 20% of the population, with 'hay fever'
(allergic rhinitis) being the most common. Asthma is a very common respiratory
disorder of ever-increasing prevalence, currently affecting over 6.5% of the
UK population, with over 200,000 patients being admitted to hospitals each
year and over 2000 deaths annually directly attributed to asthma. The
potential markets for CAT-213 are therefore enormous. However, there is
intense competition in the development of better treatments for these markets.
CAT-213, initially being developed as an intravenous injection, may also be
useful in the treatment of other conditions where raised levels of circulating
eosinophils play a significant role in pathogenesis (hypereosinophilic
syndromes).



Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ('CAT') that are forward looking statements. All
statements other than statements of historical facts included in this press
release may be forward looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934. These forward looking statements are
based on numerous assumptions regarding CAT's present and future business
strategies and the environment in which CAT will operate in the future.
Certain factors that could cause CAT's actual results, performance or
achievements to differ materially from those in the forward looking statements
include: market conditions, CAT's ability to enter into and maintain
collaborative arrangements, success of product candidates in clinical trials,
regulatory developments and competition.